Phase II study to begin for an adjunctive therapy for multiple sclerosis

To contact us Click HERE
Information provide by Thomas Mann

Transparency Life Sciences December 27, 2012

We are pleased to announce that the US Food and Drug Administration (FDA) last week cleared our Investigational New Drug Application (IND) to assess lisinopril as an adjunctive therapy for multiple sclerosis (MS), giving us the safety approval necessary to proceed with a Phase II study. You can read more about our lisinopril IND here: IND Press Release. Our lisinopril protocol made extensive use of input from a crowd of researchers and patients. If you participated by completing a Protocol Builder™ for MS, we want to extend a special word of thanks.  In keeping with our commitment to full data transparency, we have placed the lisinopril protocol on our website for your comments and suggestions.  Thank you for your participation, and have a happy new year.  Tomasz Sablinski, MD, PhD Co-founder and CEO Transparency Life Sciences, LLC

..


If you would like, you can comment to our blog posts LIKE this Blog by clicking the LIKE button - top left REMAIN up to date with MS News and EducationVisit: www.msviewsandnews.org  to register.